Related Experiment Videos
CAPD: a successful treatment in patients suffering from therapy-resistant congestive heart failure
P S König1, K Lhotta, F Kronenberg
1Department of Clinical Nephrology, University of Innsbruck, Austria.
Insights
Continuous ambulatory peritoneal dialysis (CAPD) effectively treated end-stage congestive heart failure (CHF) patients refractory to standard care. This innovative treatment stabilized patients, improving quality of life and avoiding dialysis-related complications.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Congestive heart failure (CHF) patients classified as NYHA class IV often present with refractory symptoms and end-stage disease.
- Prerenal kidney failure is a life-threatening complication in end-stage CHF, necessitating advanced treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of continuous ambulatory peritoneal dialysis (CAPD) in managing severe, treatment-refractory congestive heart failure (CHF).
- To assess the impact of CAPD on cardiac function, patient lifestyle, and survival in end-stage CHF patients.
Main Methods:
- A cohort of 13 end-stage CHF patients (NYHA class IV) received CAPD treatment at Innsbruck University Hospital.
- Patients were monitored for a minimum of six weeks, with observation periods extending up to 67 months.
Main Results:
- All 13 patients achieved cardiac recompensation, stabilizing to NYHA class II.
- No CAPD-associated complications or deaths were recorded.
- Patients experienced restoration to a normal lifestyle with reduced dependence on external support.
Conclusions:
- CAPD offers a viable and effective treatment option for end-stage CHF patients refractory to conventional therapies.
- Further research is warranted into the clinical course and hormonal markers (plasma-ANF, renin, aldosterone) of prerenal kidney failure in CHF.
Abstract:
During the last six years 13 patients suffering from congestive heart failure (CHF), refractory to conventional medical treatment and classified class IV as defined by the New York Heart Association (NYHA), were treated with continuous ambulatory peritoneal dialysis (CAPD) (1) at Innsbruck University Hospital, Department of Internal Medicine. All patients required intensive care and were end-stage. The minimum observation period was six weeks, maximum 67 months. Cardiac recompensation was effected in all patients, who were stabilized in class II after NYHA. The patient with the shortest observation period of six weeks received an orthotopic heart transplant. None of the patients died of a CAPD-associated complication. All patients were restored to a normal life style without major dependence on outside help. The occurrence and treatment of the prerenal kidney failure that causes life-threatening problems in end-stage CHF should be subject to further study with regard to its clinical course and the determination of plasma-ANF, plasma-renin and plasma-aldosterone concentration.